Novartis completes acquisition of Tourmaline Bio, delisting from Nasdaq follows
PositiveFinancial Markets

Novartis has successfully completed its acquisition of Tourmaline Bio, marking a significant step in its growth strategy. This move not only enhances Novartis's portfolio but also reflects its commitment to advancing innovative therapies. The delisting from Nasdaq follows this acquisition, which is expected to streamline operations and focus resources on developing new treatments. This is an exciting development for both companies and could lead to breakthroughs in healthcare.
— Curated by the World Pulse Now AI Editorial System









